Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration.

Pasikowska M, Walsby E, Apollonio B, Cuthill K, Phillips E, Coulter E, Longhi MS, Ma Y, Yallop D, Barber LD, Patten P, Fegan C, Ramsay AG, Pepper C, Devereux S, Buggins AG.

Blood. 2016 Jul 28;128(4):563-73. doi: 10.1182/blood-2016-01-683128. Epub 2016 Jun 1.

PMID:
27252234
2.

Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.

Pepper C, Buggins AG, Jones CH, Walsby EJ, Forconi F, Pratt G, Devereux S, Stevenson FK, Fegan C.

Leukemia. 2015 Mar;29(3):744-7. doi: 10.1038/leu.2014.308. Epub 2014 Oct 28. No abstract available.

3.

Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia.

Walsby E, Buggins A, Devereux S, Jones C, Pratt G, Brennan P, Fegan C, Pepper C.

Blood. 2014 Jun 5;123(23):3607-17. doi: 10.1182/blood-2013-12-544569. Epub 2014 Mar 17.

PMID:
24637360
4.

Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells.

Hamilton E, Pearce L, Morgan L, Robinson S, Ware V, Brennan P, Thomas NS, Yallop D, Devereux S, Fegan C, Buggins AG, Pepper C.

Br J Haematol. 2012 Sep;158(5):589-99. doi: 10.1111/j.1365-2141.2012.09191.x. Epub 2012 Jun 19.

PMID:
22712573
5.

Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2.

Pepper C, Mahdi JG, Buggins AG, Hewamana S, Walsby E, Mahdi E, Al-Haza'a A, Mahdi AJ, Lin TT, Pearce L, Morgan L, Bowen ID, Brennan P, Fegan C.

Cell Prolif. 2011 Aug;44(4):380-90. doi: 10.1111/j.1365-2184.2011.00760.x. Epub 2011 Jun 6.

PMID:
21645153
6.

Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9.

Buggins AG, Levi A, Gohil S, Fishlock K, Patten PE, Calle Y, Yallop D, Devereux S.

Br J Haematol. 2011 Jul;154(2):216-22. doi: 10.1111/j.1365-2141.2011.08725.x. Epub 2011 May 14.

PMID:
21569005
7.

CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.

Majid A, Lin TT, Best G, Fishlock K, Hewamana S, Pratt G, Yallop D, Buggins AG, Wagner S, Kennedy BJ, Miall F, Hills R, Devereux S, Oscier DG, Dyer MJ, Fegan C, Pepper C.

Leuk Res. 2011 Jun;35(6):750-6. doi: 10.1016/j.leukres.2010.10.022. Epub 2010 Nov 18.

PMID:
21093051
8.

Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription.

Buggins AG, Pepper C, Patten PE, Hewamana S, Gohil S, Moorhead J, Folarin N, Yallop D, Thomas NS, Mufti GJ, Fegan C, Devereux S.

Cancer Res. 2010 Oct 1;70(19):7523-33. doi: 10.1158/0008-5472.CAN-10-1634. Epub 2010 Aug 24.

9.

The role of Bcl-2 family proteins in chronic lymphocytic leukaemia.

Buggins AG, Pepper CJ.

Leuk Res. 2010 Jul;34(7):837-42. doi: 10.1016/j.leukres.2010.03.011. Epub 2010 Mar 31. Review.

PMID:
20359747
10.

CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment.

Patten PE, Buggins AG, Richards J, Wotherspoon A, Salisbury J, Mufti GJ, Hamblin TJ, Devereux S.

Blood. 2008 May 15;111(10):5173-81. doi: 10.1182/blood-2007-08-108605. Epub 2008 Mar 7.

PMID:
18326821
11.

Tumor-derived IL-6 may contribute to the immunological defect in CLL.

Buggins AG, Patten PE, Richards J, Thomas NS, Mufti GJ, Devereux S.

Leukemia. 2008 May;22(5):1084-7. Epub 2007 Nov 1. No abstract available.

PMID:
17972945
12.

Tumor supernatant from myeloid malignancies inhibits T-cell apoptosis and cell cycle entry independently.

Milojkovic D, Buggins AG, Devereux S, Thomas NS, Mufti GJ.

Leukemia. 2005 Sep;19(9):1699-702. No abstract available.

PMID:
16015390
13.

Effect of CD3/CD28 bead-activated and expanded T cells on leukemic B cells in chronic lymphocytic leukemia.

Patten P, Devereux S, Buggins A, Bonyhadi M, Frohlich M, Berenson RJ.

J Immunol. 2005 Jun 1;174(11):6562-3; author reply 6563. No abstract available.

14.

Antiapoptotic microenvironment of acute myeloid leukemia.

Milojkovic D, Devereux S, Westwood NB, Mufti GJ, Thomas NS, Buggins AG.

J Immunol. 2004 Dec 1;173(11):6745-52.

15.

High efficiency protein transduction of quiescent and proliferating primary hematopoietic cells.

Lea NC, Buggins AG, Orr SJ, Mufti GJ, Thomas NS.

J Biochem Biophys Methods. 2003 Mar 28;55(3):251-8.

PMID:
12706909
16.

Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab.

Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, Fishlock K, Pagliuca A, Devereux S.

Blood. 2002 Sep 1;100(5):1715-20.

PMID:
12176892
17.
18.

Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways.

Buggins AG, Milojkovic D, Arno MJ, Lea NC, Mufti GJ, Thomas NS, Hirst WJ.

J Immunol. 2001 Nov 15;167(10):6021-30.

19.

Phenotypic and functional characteristics of monocyte-derived dendritic cells from patients with myelodysplastic syndromes.

Matteo Rigolin G, Howard J, Buggins A, Sneddon C, Castoldi G, Hirst WJ, Mufti GJ.

Br J Haematol. 1999 Dec;107(4):844-50.

PMID:
10606893
20.

Effect of costimulation and the microenvironment on antigen presentation by leukemic cells.

Buggins AG, Lea N, Gäken J, Darling D, Farzaneh F, Mufti GJ, Hirst WJ.

Blood. 1999 Nov 15;94(10):3479-90.

PMID:
10552958
21.

Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies.

Buggins AG, Hirst WJ, Pagliuca A, Mufti GJ.

Br J Haematol. 1998 Mar;100(4):784-92.

PMID:
9531350
22.

In vitro immune modulation by antibodies coupled to tumour cells.

Darling D, Galea-Lauri J, Gäken J, Towner P, Kuiper M, Hollingsworth S, Hirst W, Barnard A, Buggins A, Mufti G, Farzaneh F.

Gene Ther. 1997 Dec;4(12):1350-60.

23.

Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1.

Hirst WJ, Buggins A, Darling D, Gäken J, Farzaneh F, Mufti GJ.

Gene Ther. 1997 Jul;4(7):691-9.

24.

Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors.

Gaken JA, Hollingsworth SJ, Hirst WJ, Buggins AG, Galea-Lauri J, Peakman M, Kuiper M, Patel P, Towner P, Patel PM, Collins MK, Mufti GJ, Farzaneh F, Darling DC.

Hum Gene Ther. 1997 Mar 1;8(4):477-88.

PMID:
9054522
25.

Predicting the severity of rhesus alloimmunization: monocyte-mediated chemiluminescence versus maternal anti-D antibody estimation.

Buggins AG, Thilaganathan B, Hambley H, Nicolaides KH.

Br J Haematol. 1994 Sep;88(1):199-200.

PMID:
7528528
26.

Fetal plasma tumor necrosis factor concentration in normal pregnancy.

Abbas A, Snijders RJ, Buggins AG, Layton DM, Nicolaides KH.

Fetal Diagn Ther. 1993 Jul-Aug;8(4):230-3.

PMID:
8260075
27.

Fetal plasma interferon gamma concentration in normal pregnancy.

Abbas A, Thilaganathan B, Buggins AG, Layton DM, Nicolaides KH.

Am J Obstet Gynecol. 1993 May;168(5):1414-6.

PMID:
8498420
28.

Analysis of lymphocyte phenotypes in cord blood from early gestation fetuses.

Peakman M, Buggins AG, Nicolaides KH, Layton DM, Vergani D.

Clin Exp Immunol. 1992 Nov;90(2):345-50.

29.

Fetal leucocyte count in rhesus disease.

Davies NP, Buggins AG, Snijders RJ, Noble PN, Layton DM, Nicolaides KH.

Arch Dis Child. 1992 Apr;67(4 Spec No):404-6.

30.

Blood leucocyte count in the human fetus.

Davies NP, Buggins AG, Snijders RJ, Jenkins E, Layton DM, Nicolaides KH.

Arch Dis Child. 1992 Apr;67(4 Spec No):399-403.

Supplemental Content

Loading ...
Support Center